Glioblastoma Immunotherapy Adjuvants for Glial Cell Polarization Regulation
Experimental Neurobiology · 2025-12-31 · 34 (6) · 235-247
DOI: 10.5607/en25026 ↗At a glance
Übersichtsarbeit in Experimental Neurobiology, published online on 2025-11-04. Written by Jun Seo Park and 3 co-authors. Institution: Department of Environmental Materials Science, College of Agriculture and Life Sciences, Seoul National University, Seoul 08826, Korea. Cited 8 times so far (Crossref); 76 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Research Foundation of Korea.
Abstract (original language)
Glioblastoma (GBM) remains fatal despite maximal surgical resection, temozolomide chemotherapy, and radiotherapy. Within the GBM microenvironment, tumor-educated microglia and astrocytes adopt immunoregulatory-like STAT3-high and ARG1/TGF-β-high phenotypes, respectively, which shield GBM cells from adaptive immune attack. In this review, we examine emerging adjuvant strategies designed to molecularly reprogram glial cells toward pro-inflammatory C3-high and IFN/NF-κB-high states, amplifying antitumor immunity. First, we summarize key aspects of GBM pathobiology and identify why conventional treatments fail to achieve durable control. Next, we dissect the signaling networks that govern glial phase states, including NF-κB, STAT3, IRF3, NLRP3, and cGAS-STING axes. We then provide a mechanism-centric analysis of pattern-recognition receptor (PRR) agonists, inflammasome modulators, and cyclic-dinucleotide STING agonists, integrating quantitative preclinical data with early clinical trial results. For each adjuvant, we distinguish between direct astrocytic engagement and indirect cytokine-mediated reprogramming. Modulation of glial phase states holds considerable promise for enhancing personalized vaccine efficacy and for converting immunologically "cold" GBM into a T cell-inflamed tumor. Consequently, targeting glial cell phase modulation is a highly attractive strategy for GBM immunotherapy, with the potential to maximize therapeutic benefit. Despite advances in chemo-, radio-, and checkpoint-blockade therapies, the immunosuppressive tumor microenvironment (TME) of GBM and its failure to establish memory immunity limit their impact. Tumor-polarized astrocytes and microglia form a barrier to effective T cell-mediated attack. Emerging evidence shows that redirecting glia toward pro-inflammatory phenotypes can recondition the TME, creating a more permissive landscape for immunotherapy. This review highlights glial phase reprogramming as a promising immunoadjuvant approach, emphasizing molecular circuits, synthetic modulators, and translational prospects.
Subjects
Author keywords
Authors and institutions
- Department of Environmental Materials Science, College of Agriculture and Life Sciences, Seoul National University, Seoul 08826, Korea.
- Department of Chemistry, College of Natural Sciences, Seoul National University, Seoul 08826, Korea.
- Department of Physiology and Neuroscience, Dental Research Institute, Seoul National University School of Dentistry, Seoul 08826, Korea.
Funding
- National Research Foundation of Korea
Cite
APA
Park, J. S., Lee, D. G., Min, D. H., & Lee, S. J. (2025). Glioblastoma Immunotherapy Adjuvants for Glial Cell Polarization Regulation. Experimental Neurobiology, 34(6), 235-247. https://doi.org/10.5607/en25026
Vancouver
Park JS, Lee DG, Min DH, Lee SJ. Glioblastoma Immunotherapy Adjuvants for Glial Cell Polarization Regulation. Experimental Neurobiology. 2025;34(6):235-247. doi:10.5607/en25026
BibTeX
@article{Park2025,
author = {Park, Jun Seo and Lee, Dong Geon and Min, Dal-Hee and Lee, Sung Joong},
title = {Glioblastoma Immunotherapy Adjuvants for Glial Cell Polarization Regulation},
journal = {Experimental Neurobiology},
year = {2025},
volume = {34},
number = {6},
pages = {235--247},
doi = {10.5607/en25026}
}
EUVIMED